Inserm Transfert created AndzonBio2 to accelerate neuro-inflammation innovations.
Published
Signal category
Products & Services
Quote
“Création d’AndzonBio2, dédié à l’accélération des innovations en neuro-inflammation”
— Inserm Transfert team
Company
Inserm Transfert
Votre partenaire en valorisation spécialisé dans le transfert de technologies en santé humaine et sciences de la vie
- Industry
- Biotechnology Research
- Location
- PARIS, FR
- Company size
- 119 employees
Inserm Transfert is the Inserm subsidiary dedicated to value creation and technology transfert in lifescience and human health. Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), is responsible for value creation of Inserm innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors that aspire to become involved in entrepreneurship.
Founded 2000